A standard model of Alzheimer’s disease?

References

• Jack CR Jr., Bennett DA, Blennow K, et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018 Apr;14(4):535–562. PubMed PMID: 29653606; PubMed Central PMCID: PMC5958625.
   PubMed Web of Science ®Google Scholar
• Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science. 1992 Apr 10;256(5054):184–185. PubMed PMID: 1566067.
   PubMed Web of Science ®Google Scholar
• Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med. 2016;86:595–608. PubMed PMID: 27025652.
   PubMed Web of Science ®Google Scholar
• Jucker M, Walker LC. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature. 2013 Sep 5;501(7465):45–51. PubMed PMID: 24005412; PubMed Central PMCID: PMC3963807.
   PubMed Web of Science ®Google Scholar
• Butterworth JM. The standard model: how far can it go and how can we tell? Philos Trans A Math Phys Eng Sci. 2016 Aug 28;374(2075). PubMed PMID: 27458257. DOI:10.1098/rsta.2015.0260
   PubMed Web of Science ®Google Scholar
• Holtzman DM, Morris JC, Goate AM. Alzheimer’s disease: the challenge of the second century. Sci Transl Med. 2011 Apr 6;3(77):77sr1. PubMed PMID: 21471435; PubMed Central PMCID: PMC3130546.
   PubMed Web of Science ®Google Scholar
• Weiner MW, Veitch DP, Aisen PS, et al. The Alzheimer’s disease neuroimaging initiative: a review of papers published since its inception. Alzheimers Dement. 2013 Sep;9(5):e111–94. PubMed PMID: 23932184; PubMed Central PMCID: PMC4108198.
   PubMedGoogle Scholar
• Musiek ES, Holtzman DM. Three dimensions of the amyloid hypothesis: time, space and ‘wingmen’. Nat Neurosci. 2015 Jun;18(6):800–806. PubMed PMID: 26007213; PubMed Central PMCID: PMC4445458.
   PubMed Web of Science ®Google Scholar
• Prusiner SB. Biology and genetics of prions causing neurodegeneration. Annu Rev Genet. 2013;47:601–623. PubMed PMID: 24274755; PubMed Central PMCID: PMC4010318.
   PubMed Web of Science ®Google Scholar
• Stopschinski BE, Diamond MI. The prion model for progression and diversity of neurodegenerative diseases. Lancet Neurol. 2017 Apr;16(4):323–332. PubMed PMID: 28238712.
   PubMed Web of Science ®Google Scholar
• Jack CR Jr., Bennett DA, Blennow K, et al. A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016 Aug 02;87(5):539–547. PubMed PMID: 27371494; PubMed Central PMCID: PMC4970664.
   PubMed Web of Science ®Google Scholar
• Jack CR Jr., Holtzman DM. Biomarker modeling of Alzheimer’s disease. Neuron. 2013 Dec 18;80(6):1347–1358. PubMed PMID: 24360540; PubMed Central PMCID: PMC3928967.
   PubMed Web of Science ®Google Scholar
• Catalano SM, Dodson EC, Henze DA, et al. The role of amyloid-beta derived diffusible ligands (ADDLs) in Alzheimer’s disease. Curr Top Med Chem. 2006;6(6):597–608. PubMed PMID: 16712494.
   PubMed Web of Science ®Google Scholar
• Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007 Feb;8(2):101–112. PubMed PMID: 17245412.
   PubMed Web of Science ®Google Scholar
• Nilson AN, English KC, Gerson JE, et al. Tau oligomers associate with inflammation in the brain and retina of tauopathy mice and in neurodegenerative diseases. J Alzheimers Dis. 2017;55(3):1083–1099. PubMed PMID: 27716675; PubMed Central PMCID: PMC5147514.
   PubMed Web of Science ®Google Scholar
• Hong W, Wang Z, Liu W, et al. Diffusible, highly bioactive oligomers represent a critical minority of soluble Abeta in Alzheimer’s disease brain. Acta Neuropathol. 2018 Jul;136(1):19–40. 10.1007/s00401-018-1846-7. PubMed PMID: 29687257.
   PubMed Web of Science ®Google Scholar
• Hayden EY, Teplow DB. Amyloid beta-protein oligomers and Alzheimer’s disease. Alzheimers Res Ther. 2013;56:60. PubMed PMID: 24289820; PubMed Central PMCID: PMC3978746.
   PubMed Web of Science ®Google Scholar
• Lesne SE. Toxic oligomer species of amyloid-beta in Alzheimer’s disease, a timing issue. Swiss Med Wkly. 2014;144:w14021. PubMed PMID: 25375761; PubMed Central PMCID: PMC5858692.
   PubMed Web of Science ®Google Scholar
• Attems J, Jellinger KA. Amyloid and tau: neither chicken nor egg but two partners in crime! Acta Neuropathol. 2013 Oct;126(4):619–621. PubMed PMID: 23955601.
   PubMed Web of Science ®Google Scholar
• Braak H, Del Tredici K. Reply: the early pathological process in sporadic Alzheimer’s disease. Acta Neuropathol. 2013 Oct;126(4):615–618. PubMed PMID: 23982593.
   PubMed Web of Science ®Google Scholar
• Mann DM, Hardy J. Amyloid or tau: the chicken or the egg? Acta Neuropathol. 2013 Oct;126(4):609–613. PubMed PMID: 23925566.
   PubMed Web of Science ®Google Scholar
• Small SA, Duff K. Linking Abeta and tau in late-onset Alzheimer’s disease: a dual pathway hypothesis. Neuron. 2008 Nov 26;60(4):534–542. PubMed PMID: 19038212; PubMed Central PMCID: PMC2692134.
   PubMed Web of Science ®Google Scholar
• Readhead B, Haure-Mirande JV, Funk CC, et al. Multiscale analysis of independent Alzheimer’s cohorts finds disruption of molecular, genetic, and clinical networks by human herpesvirus. Neuron. 2018 Jul 11;99(1):64–82 e7. PubMed PMID: 29937276.
   PubMed Web of Science ®Google Scholar
• Stancu IC, Vasconcelos B, Terwel D, et al. Models of beta-amyloid induced Tau-pathology: the long and “folded” road to understand the mechanism. Mol Neurodegener. 2014 Nov 18;9:51. PubMed PMID: 25407337; PubMed Central PMCID: PMC4255655.
   PubMed Web of Science ®Google Scholar
• Walker LC. Proteopathic strains and the heterogeneity of neurodegenerative diseases. Annu Rev Genet. 2016 Nov 23;50:329–346. PubMed PMID: 27893962.
   PubMed Web of Science ®Google Scholar
• Tornquist M, Michaels TCT, Sanagavarapu K, et al. Secondary nucleation in amyloid formation. Chem Commun (Camb). 2018 Jul 6. PubMed PMID: 29978862. DOI:10.1039/c8cc02204f.
   PubMed Web of Science ®Google Scholar
• Reiman EM, Langbaum JB, Fleisher AS, et al. Alzheimer’s Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis. 2011;26(Suppl 3):321–329. PubMed PMID: 21971471; PubMed Central PMCID: PMC3343739.
   PubMed Web of Science ®Google Scholar
• Sperling RA, Rentz DM, Johnson KA, et al. The A4 study: stopping AD before symptoms begin? Sci Transl Med. 2014 Mar 19;6(228):228fs13. PubMed PMID: 24648338; PubMed Central PMCID: PMC4049292.
   PubMed Web of Science ®Google Scholar
• Bateman RJ, Benzinger TL, Berry S, et al. The DIAN-TU next generation Alzheimer’s prevention trial: adaptive design and disease progression model. Alzheimers Dement. 2017 Jan;13(1):8–19. PubMed PMID: 27583651; PubMed Central PMCID: PMC5218895.
   PubMed Web of Science ®Google Scholar
• Jonsson T, Atwal JK, Steinberg S, et al. A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline. Nature. 2012 Aug 2;488(7409):96–99. PubMed PMID: 22801501.
   PubMed Web of Science ®Google Scholar
• Thomas L. Biomedical science and human health: the long-range prospect. Daedalus. 1977;106(3):163–171.
   PubMed Web of Science ®Google Scholar
• Prusiner SB, ed. Prion Diseases. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2017.
   Google Scholar
• Sandberg MK, Al-Doujaily H, Sharps B, et al. Prion propagation and toxicity in vivo occur in two distinct mechanistic phases. Nature. 2011 Feb 24;470(7335):540–542. PubMed PMID: 21350487.
   PubMed Web of Science ®Google Scholar